![Cindy Fevre](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Cindy Fevre is currently the Chief Scientific Officer at PHAXIAM Therapeutics SA since 2023.
Previously, she worked as a Research Director at Pherecydes Pharma SA. She holds a doctorate degree from the Pasteur Institute.
| Unternehmen | Position | Beginn |
|---|---|---|
| PHAXIAM THERAPEUTICS S.A. | Technik-/Wissenschafts-/F&E-Leiter | 23.06.2023 |
| Unternehmen | Position | Ende |
|---|---|---|
| PHERECYDES PHARMA | Technik-/Wissenschafts-/F&E-Leiter | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 3 |
|---|---|
Pherecydes Pharma SA
 Pherecydes Pharma SA Pharmaceuticals: MajorHealth Technology Specializes in nano technologies for pharmaceutical purposes | Health Technology |
Pasteur Institute
 Pasteur Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PHAXIAM Therapeutics SA
 PHAXIAM Therapeutics SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops red blood cell-based therapeutics for severe forms of cancer & orphan diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
